5-bromo-1-fluoro-2-methoxy-3-(trifluoromethyl)benzene | 1224604-21-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-bromo-1-fluoro-2-methoxy-3-(trifluoromethyl)benzene
• 英文别名: 5-Bromo-1-fluoro-2-methoxy-3-(trifluoromethyl)benzene
• CAS: 1224604-21-0
• 化学式: C₈H₅BrF₄O
• 分子量: 273.025
• InChiKey: JYIJZSRKYHZZBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-bromo-1-fluoro-2-methoxy-3-(trifluoromethyl)benzene 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 16.0h， 生成 5-Fluoro-4-methoxy-3-(trifluoromethyl)benzoic acid
  参考文献：
  名称：

  [EN] FTO INHIBITORS
  [FR] INHIBITEURS DE FTO

  摘要：

  Provided are a compound of Formula (I) as an FTO inhibitor with improved and selective FTO inhibition, a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.

  公开号：

  WO2024022491A1

文献信息

• 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP3153511A1

  公开（公告）日：2017-04-12

  To provide a compound useful as an active ingredient of a pharmacological composition for the treatment of urinary storage symptoms, dysuria, lower urinary tract diseases, and the like. [Solution] The inventors perfected the present invention after discovering that thiazole derivatives substituted at position 2 by pyrazinylcarbonylamino are exceptional muscarinic M3 receptor positive allosteric modulators and can be expected to serve as agents for the prevention or treatment of urinary bladder and urinary tract diseases involving bladder contraction mediated by muscarinic M3 receptors. The 2-acylaminothiazole derivatives or salts thereof of the present invention can be expected to serve as agents for the prevention or treatment of urinary bladder and urinary tract diseases involving bladder contraction mediated by muscarinic M3 receptors, e.g., underactive bladder and the like.

  提供一种化合物，作为治疗储尿症状、排尿困难、下尿路疾病等的药理组合物的有效成分。[解决方案]本发明者发现在第 2 位被吡嗪基羰基氨基取代的噻唑衍生物是一种特殊的毒蕈碱 M3 受体正异位调节剂，可望作为预防或治疗涉及毒蕈碱 M3 受体介导的膀胱收缩的膀胱和尿路疾病的药物，从而完善了本发明。本发明的2-乙酰氨基噻唑衍生物或其盐可望用作预防或治疗涉及毒蕈碱M3受体介导的膀胱收缩的膀胱和尿路疾病的药物，例如膀胱功能不全等。
• 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP3196200A1

  公开（公告）日：2017-07-26

  [Problem] To provide a compound useful as an active ingredient in a pharmaceutical composition for treating bladder storage disorders, dysuria, lower urinary tract diseases, and the like. [Solution] The inventors of the present invention have discovered that a 2-aminothiazole derivative exhibits an excellent muscarinic M3 receptor positive allosteric modulator activity, and has potential as a preventative or therapeutic agent against bladder and urinary tract diseases to which bladder contraction mediated by muscarinic M3 receptors contributes. The 2-aminothiazole derivative or salt thereof has potential as a preventative or therapeutic agent against bladder and urinary tract diseases such as, for example, dysuria including underactive bladder, and to which bladder contraction mediated by muscarinic M3 receptors contributes.

  [问题]提供一种化合物，作为药物组合物中的活性成分，用于治疗膀胱储尿障碍、排尿困难、下尿路疾病等。[解决方案]本发明的发明者发现，一种 2-氨基噻唑衍生物表现出优异的毒蕈碱 M3 受体正异位调节剂活性，具有作为膀胱和尿路疾病预防或治疗剂的潜力，膀胱和尿路疾病是由毒蕈碱 M3 受体介导的膀胱收缩造成的。2- 氨基噻唑衍生物或其盐具有预防或治疗膀胱和尿路疾病的潜力，例如，排尿困难，包括膀胱活动不足，而毒蕈碱 M3 受体介导的膀胱收缩是导致这些疾病的原因。
• 2-AMINOTHIAZOLE DERIVATIVES OR SALT THEREOF AS MUSCARINIC M3 LIGANDS FOR THE TREATMENT OF BLADDER DISEASES
  申请人：Astellas Pharma Inc.

  公开号：EP3196200B1

  公开（公告）日：2019-05-08
• 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES
  申请人：Astellas Pharma Inc.

  公开号：EP3153511B1

  公开（公告）日：2019-05-15
• US9844549B2
  申请人：——

  公开号：US9844549B2

  公开（公告）日：2017-12-19